Comparative Pharmacology
Head-to-head clinical analysis: AZITHROMYCIN versus ERYPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZITHROMYCIN versus ERYPAR.
AZITHROMYCIN vs ERYPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
None Documented
None Documented
Clinical Note
moderateAzithromycin + Norfloxacin
"Azithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateAzithromycin + Ibandronate
"Azithromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateAzithromycin + Indapamide
"Azithromycin may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateAzithromycin + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azithromycin resulting in a loss in efficacy."
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic